Sandler Laura Lee 4
4 · Oruka Therapeutics, Inc. · Filed Jan 2, 2026
Insider Transaction Report
Form 4
Sandler Laura Lee
Chief Operating Officer
Transactions
- Exercise/Conversion
Common Stock
2026-01-02$7.80/sh+5,000$39,000→ 218,084 total - Sale
Common Stock
2026-01-02$28.17/sh−8,748$246,396→ 209,336 total - Sale
Common Stock
2026-01-02$29.08/sh−3,144$91,432→ 206,192 total - Sale
Common Stock
2026-01-02$29.75/sh−1,108$32,967→ 205,084 total - Exercise/Conversion
Employee Warrant (right to buy)
2026-01-02−5,000→ 94,996 totalExercise: $7.80Exp: 2034-07-14→ Common Stock (5,000 underlying)
Footnotes (5)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.55 to $28.52, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.55 to $29.50, inclusive.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.56 to $29.92, inclusive.
- [F5]The warrant vests as to 1/4 of the underlying shares on April 3, 2025 and as to 1/48 of the underlying shares monthly from April 3, 2025.